Drugs / LMP specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01447056 | Feb 2012 → Mar 2015 | Hodgkins lymphoma, leiomyosarcoma, lymphoproliferative syndrome, nasopharyngeal carcinoma +1 | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01447056 ↗ |
| Modality | Cell therapy | “special immune system cells called LMP-specific cytotoxic T lymphocytes, a new experimental therapy.” NCT01447056 ↗ |
| Route | Intravenous | “The LMP specific CTLs will be thawed and injected IV over 1-10 minutes.” NCT01447056 ↗ |